Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-trace').style.display = (document.getElementById('cakeErr67ff7eb8ea660-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff7eb8ea660-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-code').style.display = (document.getElementById('cakeErr67ff7eb8ea660-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-context').style.display = (document.getElementById('cakeErr67ff7eb8ea660-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff7eb8ea660-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff7eb8ea660-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26013,
		&#039;title&#039; =&gt; &#039;Govt clips NPPA’s sweeping powers to control drug prices&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around ₹5,500 crore.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 23 September, 2014, http://www.thehindubusinessline.com/companies/govt-clips-nppas-sweeping-powers-to-control-drug-prices/article6439264.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674051,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26013,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Health,Health Expenditure,Health Insurance,health issues,healthcare,healthcare in india,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26013,
	&#039;title&#039; =&gt; &#039;Govt clips NPPA’s sweeping powers to control drug prices&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around ₹5,500 crore.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 23 September, 2014, http://www.thehindubusinessline.com/companies/govt-clips-nppas-sweeping-powers-to-control-drug-prices/article6439264.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674051,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26013
$metaTitle = &#039;LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices&#039;
$metaKeywords = &#039;Access to Healthcare,Health,Health Expenditure,Health Insurance,health issues,healthcare,healthcare in india,medicines&#039;
$metaDesc = &#039;
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Govt clips NPPA’s sweeping powers to control drug prices</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><br /><em>Fate of 108 drugs brought under price control in July still unclear</em></p><p align="justify">In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.</p><p align="justify">The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.</p><p align="justify">But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA's move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.</p><p align="justify">The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.</p><p align="justify">This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.</p><p align="justify">The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &quot;extraordinary circumstances&quot; and in &quot;public interest&quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.</p><p align="justify">On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.</p><p align="justify">The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.</p><p align="justify">Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &quot;Their products are, therefore, competitively priced,&quot; she added. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-trace').style.display = (document.getElementById('cakeErr67ff7eb8ea660-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff7eb8ea660-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-code').style.display = (document.getElementById('cakeErr67ff7eb8ea660-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-context').style.display = (document.getElementById('cakeErr67ff7eb8ea660-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff7eb8ea660-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff7eb8ea660-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26013,
		&#039;title&#039; =&gt; &#039;Govt clips NPPA’s sweeping powers to control drug prices&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around ₹5,500 crore.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 23 September, 2014, http://www.thehindubusinessline.com/companies/govt-clips-nppas-sweeping-powers-to-control-drug-prices/article6439264.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674051,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26013,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Health,Health Expenditure,Health Insurance,health issues,healthcare,healthcare in india,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26013,
	&#039;title&#039; =&gt; &#039;Govt clips NPPA’s sweeping powers to control drug prices&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around ₹5,500 crore.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 23 September, 2014, http://www.thehindubusinessline.com/companies/govt-clips-nppas-sweeping-powers-to-control-drug-prices/article6439264.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674051,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26013
$metaTitle = &#039;LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices&#039;
$metaKeywords = &#039;Access to Healthcare,Health,Health Expenditure,Health Insurance,health issues,healthcare,healthcare in india,medicines&#039;
$metaDesc = &#039;
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Govt clips NPPA’s sweeping powers to control drug prices</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><br /><em>Fate of 108 drugs brought under price control in July still unclear</em></p><p align="justify">In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.</p><p align="justify">The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.</p><p align="justify">But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA's move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.</p><p align="justify">The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.</p><p align="justify">This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.</p><p align="justify">The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &quot;extraordinary circumstances&quot; and in &quot;public interest&quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.</p><p align="justify">On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.</p><p align="justify">The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.</p><p align="justify">Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &quot;Their products are, therefore, competitively priced,&quot; she added. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-trace').style.display = (document.getElementById('cakeErr67ff7eb8ea660-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ff7eb8ea660-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-code').style.display = (document.getElementById('cakeErr67ff7eb8ea660-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ff7eb8ea660-context').style.display = (document.getElementById('cakeErr67ff7eb8ea660-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ff7eb8ea660-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ff7eb8ea660-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26013,
		&#039;title&#039; =&gt; &#039;Govt clips NPPA’s sweeping powers to control drug prices&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around ₹5,500 crore.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 23 September, 2014, http://www.thehindubusinessline.com/companies/govt-clips-nppas-sweeping-powers-to-control-drug-prices/article6439264.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674051,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26013,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Health,Health Expenditure,Health Insurance,health issues,healthcare,healthcare in india,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26013,
	&#039;title&#039; =&gt; &#039;Govt clips NPPA’s sweeping powers to control drug prices&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around ₹5,500 crore.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 23 September, 2014, http://www.thehindubusinessline.com/companies/govt-clips-nppas-sweeping-powers-to-control-drug-prices/article6439264.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674051,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26013
$metaTitle = &#039;LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices&#039;
$metaKeywords = &#039;Access to Healthcare,Health,Health Expenditure,Health Insurance,health issues,healthcare,healthcare in india,medicines&#039;
$metaDesc = &#039;
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Fate of 108 drugs brought under price control in July still unclear&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA&#039;s move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &amp;quot;extraordinary circumstances&amp;quot; and in &amp;quot;public interest&amp;quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &amp;quot;Their products are, therefore, competitively priced,&amp;quot; she added. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Govt clips NPPA’s sweeping powers to control drug prices</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><br /><em>Fate of 108 drugs brought under price control in July still unclear</em></p><p align="justify">In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.</p><p align="justify">The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.</p><p align="justify">But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA's move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.</p><p align="justify">The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.</p><p align="justify">This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.</p><p align="justify">The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &quot;extraordinary circumstances&quot; and in &quot;public interest&quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.</p><p align="justify">On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.</p><p align="justify">The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.</p><p align="justify">Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &quot;Their products are, therefore, competitively priced,&quot; she added. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 26013,
		'title' => 'Govt clips NPPA’s sweeping powers to control drug prices',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu Business Line
</div>
<p align="justify">
<br />
<em>Fate of 108 drugs brought under price control in July still unclear</em>
</p>
<p align="justify">
In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.
</p>
<p align="justify">
The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.
</p>
<p align="justify">
But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA's move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.
</p>
<p align="justify">
The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.
</p>
<p align="justify">
This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.
</p>
<p align="justify">
The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &quot;extraordinary circumstances&quot; and in &quot;public interest&quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.
</p>
<p align="justify">
On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around ₹5,500 crore.
</p>
<p align="justify">
The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.
</p>
<p align="justify">
Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &quot;Their products are, therefore, competitively priced,&quot; she added. 
</p>',
		'credit_writer' => 'The Hindu Business Line, 23 September, 2014, http://www.thehindubusinessline.com/companies/govt-clips-nppas-sweeping-powers-to-control-drug-prices/article6439264.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4674051,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 26013,
	'metaTitle' => 'LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices',
	'metaKeywords' => 'Access to Healthcare,Health,Health Expenditure,Health Insurance,health issues,healthcare,healthcare in india,medicines',
	'metaDesc' => '
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The...',
	'disp' => '<div align="justify">-The Hindu Business Line</div><p align="justify"><br /><em>Fate of 108 drugs brought under price control in July still unclear</em></p><p align="justify">In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.</p><p align="justify">The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.</p><p align="justify">But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA's move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.</p><p align="justify">The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.</p><p align="justify">This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.</p><p align="justify">The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &quot;extraordinary circumstances&quot; and in &quot;public interest&quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.</p><p align="justify">On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.</p><p align="justify">The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.</p><p align="justify">Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &quot;Their products are, therefore, competitively priced,&quot; she added. </p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 26013,
	'title' => 'Govt clips NPPA’s sweeping powers to control drug prices',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu Business Line
</div>
<p align="justify">
<br />
<em>Fate of 108 drugs brought under price control in July still unclear</em>
</p>
<p align="justify">
In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.
</p>
<p align="justify">
The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.
</p>
<p align="justify">
But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA's move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.
</p>
<p align="justify">
The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.
</p>
<p align="justify">
This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.
</p>
<p align="justify">
The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &quot;extraordinary circumstances&quot; and in &quot;public interest&quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.
</p>
<p align="justify">
On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around ₹5,500 crore.
</p>
<p align="justify">
The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.
</p>
<p align="justify">
Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &quot;Their products are, therefore, competitively priced,&quot; she added. 
</p>',
	'credit_writer' => 'The Hindu Business Line, 23 September, 2014, http://www.thehindubusinessline.com/companies/govt-clips-nppas-sweeping-powers-to-control-drug-prices/article6439264.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'govt-clips-nppas-sweeping-powers-to-control-drug-prices-4674051',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4674051,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 26013
$metaTitle = 'LATEST NEWS UPDATES | Govt clips NPPA’s sweeping powers to control drug prices'
$metaKeywords = 'Access to Healthcare,Health,Health Expenditure,Health Insurance,health issues,healthcare,healthcare in india,medicines'
$metaDesc = '
-The Hindu Business Line



Fate of 108 drugs brought under price control in July still unclear


In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.


The...'
$disp = '<div align="justify">-The Hindu Business Line</div><p align="justify"><br /><em>Fate of 108 drugs brought under price control in July still unclear</em></p><p align="justify">In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices.</p><p align="justify">The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs.</p><p align="justify">But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA's move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers.</p><p align="justify">The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices.</p><p align="justify">This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines.</p><p align="justify">The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in &quot;extraordinary circumstances&quot; and in &quot;public interest&quot;. The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low.</p><p align="justify">On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore.</p><p align="justify">The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking.</p><p align="justify">Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. &quot;Their products are, therefore, competitively priced,&quot; she added. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Govt clips NPPA’s sweeping powers to control drug prices

-The Hindu Business Line Fate of 108 drugs brought under price control in July still unclear In a booster for pharmaceutical companies, the Government has ensured that the National Pharmaceutical Pricing Authority (NPPA) no longer enjoys sweeping powers to control drug prices. The NPPA on Tuesday withdrew the guidelines it issued on May 29 that allowed the Authority to control drug prices in public interest. Based on this, it had subsequently capped prices of 108 formulations, including cardiac and diabetes drugs. But, now, the NPPA has been asked to withdraw the guidelines. The latest notification is silent on the fate of these 108 formulations. And to add to the uncertainty on the price cuts are the two ongoing cases the pharma industry had filed against the NPPA's move. According to an internal guideline issued by the Authority on September 22, the NPPA moves comes at the direction of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers. The NPPA, in its May 29 notification, had decided to fix the prices of non-scheduled drugs as well, if there was a huge variation in inter-brand prices. This notification soon resulted in the prices of 108 non-scheduled drugs, which did not feature in the National List of Essential Medicines, getting capped by NPPA on July 10. This was contested by pharmaceutical companies, many of which took the matter to court on the ground that these drugs did not form part of the national list of essential medicines. The NPPA had invoked Paragraph 19 of the Drug Price Control Order. Under this, it has the authority to extend price control over medicines outside of the essential medicines list in "extraordinary circumstances" and in "public interest". The companies also argued that bringing these drugs under a controlled price regime made manufacturing them economically unviable because volumes were low. On September 18, the Delhi High Court directed the Government and the pharmaceutical companies to resolve the pricing issue expeditiously. Some of the drugs which came under price control following the May order were: Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril. These have an estimated market of around 5,500 crore. The latest move will benefit MNCs more than the domestic players as the former usually price their products much higher than the competition and then derive 100 per cent of their sales from the domestic market, said Sarabjit Kour Nangra, Vice-President Research (Pharma), Angel Broking. Domestic companies that do not have a huge exposure to the local market will be insulated to a large extent as pricing is not the key growth driver for them. "Their products are, therefore, competitively priced," she added.